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1.   INTRODUCTION 
 
Infantile hemangiomas (IHs) are frequently encountered in paediatric 
population. In fact, they represent the most common infantile neoplasm.  
IHs are benign vascular tumors which affect 10-12% of infants by 
the first year of life; they are more common in girls more than in boys 
(3:1), with an incidence of 1%-2,6% in newborn babies. 
They are very frequent in premature infants with low weight at birth 
(23%); furthermore, their incidence is increased when a placental trauma or 
placental complications (placenta previa, chorionic villous sampling and 
amniocentesis) occur during gestation. (1) 
Natural history of IHs is characterized by a predictable pattern of 
progression through three phases: IHs are not usually present at birth, but 
they appear during the first days or weeks of life, then they are 
characterized by a rapid proliferation until 10th-12th month of life followed 
by a spontaneous involution, of variable duration, that usually leads to the 
regression of IHs. Sometimes IHs are preceded by precursors yet present at 
birth. They are going to develop to IHs during the following weeks or 
months. 
Involution is characterized by progressive softening of the tumor and 
fading of the bright red color with development of multiple white-grey 
areas on the surface of IHs. 
Regression can be complete in some cases, but in other cases, 
residual sequelae may persist, such as fibro-fatty residual tissue, scarring, 
atrophic skin and telangiectasias. From a clinical point of view, they appear 
as red or purplish-blue masses ranging in size from a few millimeters to 
several centimeters. They may be single (80%) or multiple (20%), with a 
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tense or soft consistency, more or less floating compared to the underlying 
layers and, basically, not painful. 
Moreover, if they affect only the skin, they may be superficial and 
bright red colored; they are dark bluish if they are subcutaneous and if they 
involve both the skin and the subcutaneous tissues they are mixed. 
They occur more frequently in the head and neck region (60%), 
followed by the trunk (25%) and limbs (15%). Usually superficial IHs 
complete their growth during the first 5 months of life, while deep IHs tend 
to grow longer. 
Histopathologically, IHs are masses of proliferating and plump 
endothelial cells with high mitotic activity and narrow vascular channels. 
The endothelial cells expresses the placental markers GLUT1, the glucose 
transporter protein 1, CD14, CD32 and merosin, which differentiate IHs 
from other vascular anomalies and from normal skin. (2) 
They must be differentiated from congenital hemangiomas, which 
are vascular neoplasms fully developed and present at birth, without the 
tendency to further growth. Congenital hemangiomas are GLUT1 negative 
and they can be classified into two types: RICH (rapidly involuting 
congenital hemangiomas) and NICH (non-involuting congenital 
hemangiomas).  
RICH are large tumours which often reach 5 cm in diameter, bright 
red or purplish colored, with a central depression lined by telangiectasias 
and a different color compared to the edges. They are usually located in the 
head and limbs. 
NICH are most often flat, localized in the limbs or face and they 
show telangiectasias. 
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IHs must be differentiated also from vascular malformations, (such a  
port-wine stains, kaposiform hemangioendothelioma, tufted angioma) and 
pyogenic granuloma. 
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2.   PATHOGENESIS 
 
Different hypothesis exist on the origins of IHs, but none of these by 
self are able to explain the development of all the different clinical forms of 
IHs; the pathogenesis of  IHs is complex, not completely elucidated and it 
probably arises from an integration of all these theories. 
Two major hypothesis are competitive: the intrinsic hypothesis and 
the extrinsic hypothesis. 
As a result of some studies, the first suggests that IHs derive from a 
somatic mutation in one or more genes involved in endothelial cell 
proliferation. IHs may be arise from an uncontrolled clonal expansion of 
endothelial cells in the skin. 
Studies showed that all hemangioma-derived endothelial cells 
present the same X-inactivation pattern, moreover proliferating 
hemangiomas present somatic mutations of vascular endothelial growth 
factor (VEGF-R) receptors.  
The second theory suggests that growth factors, tissue hypoxia and 
alterations in the microenvironment may stimulate the hemangiomagenesis. 
Hypoxia is a powerful inducer of vasculogenesis as an up regulator 
of GLUT1; placental hypoxia seem to correlate with IHs. 
In proliferating IHs some growth factors and their receptors such as 
VEGF-R2, angiopoietin receptors Tie-1 and Tie-2, angiopoietin-2, are 
over-expressed, leading to an increased angiogenesis. 
Finally, there is the theory that IHs may arise from the clonal 
expansion of cells derived from placental endothelial cells. Invasive 
procedures, such as chorionic villous sampling, have been suggested to 
increase the occurrence of IHs, because they cause dislodgment of 
placental cells which enter the circulation and embolize the developing 
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fetus. (3) Supporting this theory, many of the molecular markers of IHs are 
also expressed by normal placental fetal microvessesl: laminin, merosin, 
Lewis Y antigen, Fc gamma receptor II, GLUT1. Another molecule 
expressed in hemangioma endothelial cells is the type-3 iodothyronine 
deiodinase normally expressed in the placenta: this enzyme inactivates 
thyroid hormones, so it can be responsible for children’s  hypothyroidism  in  
case of large hemangiomas. (4)  
In spite of these scientific evidences, it is not still possible to 
conclusively establish that IHs derives from placenta. 
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3.   RARE AND COMPLICATED FORMS OF INFANTILE   
HEMANGIOMAS 
 
Large (diameters larger than 5 cm) or segmental facial and 
lumbosacral IHs represent rare but potential life-threatening forms of IHs. 
When a large or segmental IH involves the face, some clinical and 
instrumental evaluations are mandatory to exclude a PHACES syndrome 
(Posterior fossae malformations, Hemangiomas, Arterial anomalies, 
Cardiac anomalies, Eye anomalies and Sternal defects) and/or airways 
involvement if the IH is localized in the beard region. In the case of a facial 
hemangioma an increase rate of visits and a rapid treatment may be 
necessary to avoid severe complications, functional impairment or 
disfigurement (periorbital and perioral IHs, auricular and nasal 
localization). IHs involving the periorbital area may cause amblyopia and 
strabismus, those localized in the nose (Cyrano) and in the ears may cause 
permanent alteration of the cartilage structure, finally, those localized in the 
lips may ulcerate with feeding difficulties. 
Cutaneous IHs localized in the mandibular region are frequently 
associated with airways involvement, so even in apparent absence of 
airways symptoms, an otolaryngology evaluation and eventually a 
laryngoscopy must be performed. 
Lumbosacral or perineal IHs may be a sign of underlying structural 
anomalies, especially spinal dysraphism and lipomyelomeningocele. 
Some acronyms highlight different structural anomalies associated 
with IHs: SACRAL syndrome (Spinal dysraphism, Anogenital, Cutaneous, 
Renal and Urological Anomalies with Lumbosacral hemangioma), PELVIS 
syndrome (Perineal hemangioma, External genitalia malformations, 
Lipomyelomeningocele, Vesico-renal abnormalities, Imperforate anus and 
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Skin tags), LUMBAR syndrome (Lower body hemangioma and other 
cutaneous defect, Urogenital anomalies, Ulceration, Myelopathy, Bone 
deformities, Anorectal malformations, Arterial anomalies and Renal 
anomalies). 
Magnetic resonance (MRI) is the best evaluation to detect spinal    
abnormalities which interest about 50% of children with lumbosacral large 
hemangioma. In these patients MRI is more sensitive than ultrasound, but 
in children younger than 3 months even MRI may not be enough sensitive 
and the study must be repeated at 6 months of age. 
When a child is affected by 5 or more IHs, diffuse neonatal 
hemangiomatosis and/or internal organs involving must be investigated. 
Hepatic ultrasound, thyroid function and heart evaluation must be 
performed to exclude the rare complications consisting in hepatic massive 
involvement, severe hypothyroidism and congestive heart failure. 
Furthermore, neonatal diffuse hemangiomatosis must be excluded: it 
is a rare, potential life-threatening condition, characterized by multiple 
cutaneous (more than 5) and visceral hemangiomas involving at least 3 
organs, onset in the neonatal period and in absence of the malignant 
transformation. 
Segmental extremity hemangiomas, finally, show a higher risk of 
complications such as ulceration. 
The commonest IHs complications are ulceration and subsequent 
pain, bleeding and infection, impairment of physiological functions and 
possible disfigurement. 
Ulceration is the most common complication (15-25% of IHs), it is 
usually preceded by an early whitening of the IHs surface (child aged less 
than three months, to differentiate the signs of IHs involution), and it 
occurs more frequently in segmental, large size, mixed subtype IHs and in 
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those localized in the lip, neck, anogenital area, mucosae and intertriginous 
folds. 
Large size or segmental IHs are potentially life-threatening for their 
mass effect: they may cause compression or obstruction of internal organs 
with impairment of their functions. Periorbital IHs can compromise the 
vision, perioral and lip IHs can interfere with feeding and bulky IHs of the 
head, neck and ears may lead to positional anomalies such as torticollis. 
IHs with facial distribution or involving breasts and genitalia may 
cause permanent unaesthetic disfigurement and risk of scarring. (5) 
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4.   TRADITIONAL THERAPIES 
  
Although the majority of IHs do not require intervention because 
they spontaneously regress without any risk of later complications, about 
10-20% of IHs need early treatment. 
Indications for active therapies are: 
1) Risk of ulceration 
2) Prevent and avoid life-threatening complications 
3) Prevent or treat functional impairment or pain 
4) Prevent unaesthetic disfigurement 
Even if a labeled protocol for treating IHs does not exist, 
corticosteroids have been considered until now the first choice therapy. 
Systemic steroid therapy (prednisolone and prednisone) is usually 
administered at 2-3 mg/kg/die in a single daily dose: this treatment is very 
effective during the proliferative phase of IHs. The commonest side effects 
are gastrointestinal disturbances and irritability, weight gain, Cushing’s 
disease, hypertension, adrenal suppression and immunosuppression. 
During this treatment patients need periodic clinical evaluation and 
monitoring of blood pressure, glucose levels and weight. 
Steroid therapy can be performed also by intralesional administration 
(triamcinolone 10 mg/ml), especially for bulky IHs localized in the lip, 
nose and sometimes for periorbital lesions. Possible side effects are 
bleeding, skin atrophy and infection; for periorbital IHs some cases of 
retinal artery damage and consequently blindness have been described. 
The mechanism of steroid treatment is not clear, but they probably 
act directly on hemangioma endothelial cells; some studies demonstrated 
that prednisolone inhibits angiogenesis. 
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Other medical treatments are considered as a second or third choice 
in case of IHs that do not respond to corticosteroids. 
Interferon   α   (recombinant   INF   2α   and   2β)   has   an   antiangiogenetic  
activity and it can be used for treatment of difficult hemangioma; it is 
administered with daily subcutaneous injections at dose of 1-3 million 
U/mq; its main side effects are transient neutropenia and fever, but it may 
cause irreversible neurotoxicity so its use is very rare. 
Vincristine is a vinca alkaloid chemotherapeutic agent frequently 
used for treat haematological and solid tumor malignancies. It can be used 
for treatment of life-threatening IHs when other therapies have failed and 
for Kasabach-Merritt syndrome. It is administered intravenously at 1-1,5 
mg/mq weekly. 
Vincristine has many side effects and its use needs oncologists and 
haematologists collaboration. 
Bleomicin is an antineoplastic antibiotic used for the treatment of 
solid tumours of the head and neck, lymphomas and testicular carcinoma. 
Bleomicin is administered intralesionally for the treatment of IHs and its 
main side effects are ulceration and hyperpigmentation. Its efficacy has 
been reported in different studies and it seems to be due to the inhibition of 
neovascularization. (6-7) Some studies have reported the effectiveness of 
cyclophosphamide in the treatment of complicated, life-threatening 
hemangiomas, after failure of corticosteroid therapy. (8) 
Cyclophosphamide is another chemiotherapeutic drug usually 
employed for treat malignancies such as lymphomas, leukemia and solid 
tumors and some autoimmune disorders. 
Other treatments are lasers therapy and surgery. Pulsed-dye laser and 
Nd:YAG laser are used for superficial component of IHs and for ulcerated 
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IHs. Pulsed-dye laser is also used to treat residual telangiectasias in 
involuted IHs. 
Surgery is sometimes necessary for chronic ulcerated IHs, bulky and 
peduncolated IHs, for those which do not respond to medical treatment and 
to reduce fibro-fatty residuum after the involutive phase. 
Topical traditional therapies consist of application of potent topical 
steroids used for superficial IHs or imiquimod cream. (9-10-11-12-13). 
Possible side effects of potent steroids are skin atrophy, striae and risk of 
systemic absorption; common side effects of imiquimod cream are 
crusting, irritation and ulceration. 
The topical treatment of ulcerated IHs consists in the application of 
emollients associated with non-adherent dressings such as hydrocolloid or 
petrolatum impregnated gauze. Other treatments include metronidazole gel 
or cream and topical platelet derived growth factor gel. 
Furthermore, it is very important to prevent and treat pain by using 
lidocaine 2-5% ointment applied 3-4 times daily directly on the ulceration. 
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5.   BETA BLOCKERS AND HEMANGIOMAS 
 
Propranolol is a non-selective beta-blocker, so it equally   binds   β1  
and   β2   adrenoreceptors   leading   to   a   reduction   of   heart   rate   and   cardiac  
output. At the beginning, this effect is hampered by a peripheral 
vasoconstriction. Moreover propranolol causes reduction in blood flow and 
pressure.  
Propranolol was the first beta-blocker used for the treatment of 
angina pectoris; in the 1950s it was invented by Sir James Black who 
received the Nobel Prize in Medicine for this reason in 1988. (14-15) 
At present its use in children is licensed for the treatment of 
hypertension, cardiovascular diseases and thyrotoxicosis; propranolol has a 
very good safe profile and in children it is used in doses as high as 7 
mg/kg/die. It has potential and well known side effects: the most common 
are hypoglycemia, hypotension, bradycardia, exacerbations of asthma and 
mood disturbances. After more than 40 years of propranolol utilization in 
children, no case of death or life-threatening complications have been 
reported. (16) 
From June 2008 propranolol became increasingly popular for the 
treatment of infantile hemangiomas: Léauté-Labrèze et al. reported in a 
letter to The New England Journal of Medicine the antiproliferative effect 
of propranolol on infantile hemangiomas. (17)  
This serendipitous discovery was an incidental finding: they 
observed the regression of large and life-threatening IHs in 2 children 
treated with propranolol for concomitant cardiac diseases. Furthermore, the 
authors decided to treat another 11 patients affected by severe and 
disfiguring IHs with propranolol. In all patients they observed a rapid 
clinical regression of IHs, supported also by ultrasound examination data 
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which demonstrated reduction in thickness and increased in the resistive 
index of vascularization of IHs. Sans et al. reported a follow up study on 21 
additional patients successfully treated with propranolol. (18) 
From the original publication in 2008, several papers (more than 
150) emphasized the effectiveness of propranolol on IHs. Other beta-
blockers such as acebutol and nadolol have also been used for IHs, but the 
majority of reports regard the propranolol. Numerous case reports and 
some case series have been published supporting the efficacy and safety of 
propranolol for IHs.  
Laforgia et al. and Manunza et al. reported the efficacy of 
propranolol for IHs in 23 and 30 patients respectively. (19-20)  
Qin ZP. et al. successfully treated 58 children affected by severe IHs 
with propranolol: only 1,7% had poor response to the therapy. (21)  
Leboulanger N. et al. reported a multicentric, retrospective study of 
14 children affected by airways IHs treated with propranolol. All 
hemangiomas regressed with noticeable improvement of the airways 
stenosis; recurrences were noted in 4 patients after an early interruption of 
therapy. Two of these patients developed a resistance to beta-blockers, in 
fact the IHs do not respond to re-introduction of propranolol. One patient 
presented a severe episode of asthma, so propranolol was stopped and 
successfully substituted with acebutol. (22)  
Hogeling M. et al. described a small randomized controlled trial of 
19 patients treated with propranolol and 20 patients treated with placebo, 
reporting the efficacy and safety of propranolol therapy. (23)  
Propranolol was administrated at a dosage of 1 mg/kg/die divided 
into 3 daily doses for the first week then increased to 2 mg/kg/die divided 
into 3 daily doses. This study reports the efficacy and safety of this therapy: 
only 2 patients do not respond completely to the treatment. No 
 16 
hypotension, hypoglycemia or bradycardia were observed, but cold 
extremities, sleep disturbances and dental caries were reported.  
Schiestl C. et al. reported a retrospective study on 25 patients treated 
with propranolol for problematic IHs. Dosage was 1mg/kg/die in 3 daily 
doses for the first day, then increased to 2 mg/kg/die from the second day. 
All the IHs responded to propranolol, only 2 patients presented mild 
regrowth and darkening of color after stopping the therapy. Reported side 
effects were sleep disturbances in 2 children and anxiety in 1 child: these 
were mild, self-limited and transient. (24)  
Holmes et al. described a prospective study on 31 patients affected 
by proliferating hemangiomas treated with propranolol. They reported a 
regression rate of 87%, rebound rate of 24% after cessation of treatment 
and little and transient side effects. All patients with rebound were re-
treated succesfully with propranolol. (25)  
Buckmiller et al. described 32 patients affected by IHs treated with 
propranolol revealing good response in 50% of patients, partial response in 
47% and no response only in 3%. (26)  
Zaher et al. reported the efficacy and safety profile of oral 
propranolol at the dosage of 2 mg/kg/die, divided into 3 doses, in the 
treatment of 30 children with problematic IHs: 60% of patients showed an 
excellent response, 20% a good response (reduction of more than 50% in 
the size of IH), 16,6% a fair response (reduction of less than 50% in the 
size of IH), and no response in 3,3% (one patient); 17,24% of patients 
showed rebound of growth after cessation of therapy. No side effects were 
observed. (27)   
A large retrospective study describes 71 patients (from four different 
hospitals in Argentina and Spain) treated with oral propranolol at a dosage 
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of 2 mg/kg/die divided into 2 daily doses. The result of this study is that 
propranolol is a rapid, effective and safe therapy for IHs. (28)  
Bertrand J. et al. reported a retrospective study on 35 patients treated 
with propranolol for severe IHs. Rapid improvement was observed while 
no serious side effects were collected. (29)  
Katona G. et al. described a retrospective study on 22 children 
affected by head and neck IHs and treated with propranolol. They 
concluded that propranolol is a highly effective therapy, with rapid 
reduction of IHs during the first week of treatment followed by a slower 
improvement. (30)  
Shupp JC. et al. reported a study on 55 children treated with 
propranolol for IHs. Dosage was 2 mg/kg/day for a mean duration of 
treatment of 5,8 months. Mean age at the beginning of therapy was 6 
months. Eight patients showed a complete regression, 46 partial regression 
and 1 had no response. Thirteen patients showed some side effects, but 
only 1 patient needed an early withdrawal of the therapy for aggravation of 
preexisting bronchial asthma. Six patients showed recurrences after 
termination of the first course of therapy, so a second propranolol treatment 
was necessary. No relapses were observed after the second cycle of 
therapy. (31) 
Gan Li et al. reported one of the largest retrospective study involving 
109 Chinese patients treated with propranolol 2 mg/kg/day for IHs. 
Regression was observed in 108 patients, of which 19 showed complete 
regression while 89 partial regression. Only 1 patient had no response. 
Twenty-three children had some adverse but mild side effects and only 4 
children needed an early therapy withdrawal. Relapses occurred in 9 
patients who needed a second course with propranolol which was 
successful for all. (32)  
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Hermans D.J.J. et al. reported one of the largest prospective study on 
174 patients affected by IHs treated with propranolol in the Netherlands. A 
target dosage of 2-2,5 mg/kg/day was administered to the patients: they 
observed a good response in 173 patients; only 4 patients required a second 
course of propranolol for recurrences and this second treatment was 
successful in all patients. Possible side effects were noted in 108 patients, 
but only 15 patients required a dose reduction while in 1 patient, with 
extreme nocturnal restlessness, propranolol was switched to atenolol, 
obtaining a better sleep and a good regression of IH. Only 1 patient, who 
was extremely premature, required early discontinuation of the therapy due 
to a severe hypotension, drowsiness and cold-extremities. The main side 
effects collected in this study were hypotension, wheezing especially 
during upper respiratory tract infections and sleep disturbances. (33)  
Jian D. et al. performed a study on 97 Chinese patients treated with 
propranolol at dosage of 2 mg/kg/die for IHs, in order to assess the safety 
of this therapy. All patients were examined at follow up for a period from 6 
to 12 months. Some side effects were reported: bronchial hyperreactivity, 
cyanosis and cold extremities, agranulocytosis and low body temperature. 
Most of these side effects appeared in the first week of therapy, period that 
needs the most strictly surveillance. (34)  
Zvulunov et al. reported 42 patients affected by IHs successfully 
treated with propranolol beyond the proliferative phase, to indicate that this 
therapy is effective also in the post-proliferative phase. In this retrospective 
study only patients aged more than 12 months and those with IHs without 
signs of growth were enrolled. Median age of the patients in treatment was 
22 months. Mean duration of the therapy was 3,6 months. The therapy was 
discontinued when the lesion stopped to respond to the treatment. Mild side 
effects were reported in 4 children consisting in sleep disturbances and 
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transient dyspnea. None of patients showed complete involution, but 
aesthetic improvement was reported in the whole group. This report allows 
to treat with propranolol every child with late IH residual, before a   
surgery. It is unclear how propranolol acts in the post-proliferative phase. 
(35) (These data are summarized in table 1) 
All reported case series demonstrate the high efficacy of propranolol 
in inducing regression in IHs, even in those non responsive to 
corticosteroids or other therapies. Furthermore, propranolol therapy did not 
frequently show severe side effects, on the contrary to systemic steroids, 
INFα,  vincristine  and  bleomicine. 
The most common reported side effects are hypotension, pulmonary 
symptoms, hypoglicemia, bradycardia, sleep disturbances, cold extremities, 
gastrointestinal problems. Two cases of hyperkaliemia were reported. 
A case of tumor lysis syndrome and hyperkaliemia after propranolol 
therapy in ulcerate IH was described in a 33-days-old child: it can be 
considered a rare complication of ulcerated IHs treated with propranolol. In 
the case reported no treatment or early propranolol withdrawal was 
necessary because the electrolytic alterations were mild and self-limited. 
(36)  
Another case of severe hyperkaliemia was reported in a 17-week-old 
preterm girl affected by a large and ulcerated IH during the first days of 
propranolol intake. In this case, the patient required a further treatment to 
normalize the serum potassium level but did not require early propranolol 
discontinuation; the hemangioma successfully responded to propranolol. 
(37)   
Nowadays a well standardized protocol for IHs treatment is lacking, 
as well as for the use of propranolol. The first consensus conference about 
the use of propranolol for IHs was performed in Chicago on December 9, 
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2011; a multidisciplinary team discussed and agreed on a number of 
recommendations arising from a review of existing evidence. (38)  
Recommendations for the initiation and use of propranolol for IHs: 
only patients affected by IHs with high risks for complications must be 
treated. 
Dermatological visit and recruitment for therapy, cardiological 
assessment with electrocardiography (ECG), blood pressure measurement 
and pediatric evaluation for blood glucose level and routine screening 
should be performed. For patients affected by PHACE syndrome, 
echocardiography, magnetic resonance (MRI) or angiography of head and 
neck area are mandatory. Every patient must be individually evaluated for 
risks and benefits of propranolol therapy. The propranolol treatment must 
be managed in close consultation with cardiologists. 
Propranolol should be administrated into 3 daily doses, at the 
initially dosage of 1 mg/kg/die and after a week increased to  2-3 mg/kg/die 
if it is well tolerated. At the end of the therapy, propranolol should be 
gradually tapered in 2-3 weeks. The treatment should be performed through 
the proliferative phase of IHs or until regression. If rebound occurs, 
propranolol should be re-introduced. 
Patients aged less than 8 weeks of gestationally corrected age or with 
comorbidities should be hospitalized for the start of the therapy, while 
patients over 8 weeks of gestationally corrected age do not require any 
hospitalization. All patients should be monitored with heart rate and blood 
pressure during the first hours after initiation and after every dose increase. 
In order to reduce risk of hypoglicemia, which is age-related, patients 
should be fed frequently (at least every 4 hours for the infants aged less 
than 6 weeks) and propranolol should be discontinued in case of illness. 
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Particular attention must be taken for preterms and for patients who need 
concomitant medications. 
The mechanism of action of propranolol in the treatment of IHs is 
not clearly understood. Beta-adrenoreceptors are part of a G-protein 
coupled receptor super family, expressed on endothelial cells, which 
activate adenylate cyclase. This cascade of signals leads to a nitric oxide 
synthesis in the endothelial cells: this results in vasodilatation. Beta-
blockers act blocking this signaling. The rapid changes observed in IHs 
during the first 48 hours are due to vasoconstriction due to the decreased 
release of nitric oxide. The intermediate effects of propranolol are due to a 
reduced expression of angiogenetic factors, which play a role in the 
endothelial cells proliferation, to a down-regulation on the renin-
angiotensin axis causing a reduction of angiogenesis. The long-term effects 
are due to an up-regulation on the caspase cascade leading to induction of 
apoptosis. (39-40)  
Until now several cases of recurrences after propranolol therapy have 
been reported, although the rate and the possible causes have not been 
explained. Regrowth of IHs after corticosteroid treatment is well-known 
and frequently reported. Concerning propranolol treatment, IHs with deep 
component seem to be more susceptible to recur after propranolol 
cessation.  
Bagazgoitia et al. reported 26 patients treated with propranolol with 
a recurrence rate of 19% (5 patients), observed 9 months after the end of 
the therapy. The span of time from withdrawal to recurrence ranges from 0 
to 6 months, 4 patients presented partial recurrence while 1 patient 
complete recurrence. Possible causes of recurrences were explained by 
authors:  early therapy withdrawal (before the end of the proliferative 
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phase), but also a long proliferative phase; VEGF-R involvement and an 
incomplete apoptosis in the endothelial cells. (41) 
It is clear that propranolol have to be administered until the end of 
the proliferative phase that in the majority of severe IHs occurred at 10th-
12th month of age. However it is difficult to predict which IH will have a 
late proliferative phase, so it is very complicated to define a fixed protocol 
of treatment: the duration of the therapy must be individualized. IHs are 
very heterogeneous and their clinical evolution is unpredictable. The time 
of relapses after propranolol withdrawal is heterogeneous, so the patients 
must be followed for at least 6 months. 
Izadpanah et al. reported a systematic review of the literature from 
1965 to 2012 and a meta-analysis to compare the use of propranolol versus 
corticosteroids in the treatment of IHs, suggesting that propranolol therapy 
could be superior to the steroid therapy. (42) 
Their results showed that less than 90% of patients treated with 
steroids responded to the therapy versus 99% of patients treated with 
propranolol. The meta-analysis demonstrated a resolution rate of 97% 
compared to 71% for propranolol versus systemic corticosteroids. The 
complication rate in the cases treated with steroids is more than double if 
compared to propranolol therapy.  
Peridis et al. performed another meta-analysis and demonstrated the 
superiority in the effectiveness of propranolol and the less side effects 
versus the traditional therapy used in the airways hemangiomas treatment 
such as corticosteroids, laser CO2 and vincristine. (43)  
Nowadays topical propranolol treatment is anecdoctal, but some 
cases of superficial hemangiomas have been successfully treated. Topical 
beta blocker is available in form of timolol solution 0,25% or  0,5% 
eyedrops or timolol maleate gel-forming 0,5% or 0,1%; moreover, a 
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galenic formulation propranolol cream 1% can be made. It must be applied 
twice a day on the hemangioma for a variable period in relation to the 
individual response. After the first case-report published in 2010 by Guo et 
al., regarding the utility of topical beta blockers in IH, especially timolol 
maleate, several case reports and some studies were described. (44-45-46-
47)  
The results are encouraging, timolol maleate seems to induce 
regression in the superficial component of IHs and it could be a substitute 
when systemic propranolol is contraindicated. However, timolol maleate as 
well as systemic propranolol, may cause side effects due to its systemic 
absorption. Even if the timolol maleate percutaneous absorption and its 
bioavailability on intact skin are unknown, however physicians who 
prescribe this drug must be aware of the signs and symptoms of potential 
systemic absorption. More important systemic absorption occurs when 
timolol maleate is applied near or on mucosal surfaces, on ulcerated 
hemangiomas and on thinner skin sites. 
Gel-forming solution seems to be less absorbed and safer than 
timolol maleate solution for the treatment of IHs. Caregivers should be 
instructed to use one or two drops per application to avoid beta blockers 
overdose. Local cutaneous side effects due to topical timolol application 
are alopecia, localized or generalized rash, psoriasiform dermatitis and 
angioedema. (48) 
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6.   OUR EXPERIENCE 
 
From 2008 to 2012 in our Paediatric Outpatient Service of 
Dermatology of the University of Bologna, a pilot, monocentric, open 
label, not randomized and not controlled clinical study was conducted by a 
medical team made up of Dermatologists, Pediatricians, Radiologists and 
Cardiologists. Local ethical approval was obtained before starting the 
study. The main objective of the study was to determine the efficacy and 
the tolerability of systemic propranolol in the treatment of infantile 
hemangiomas. 
Materials and methods: 
All patients were enrolled after a dermatological examination which 
also included an iconography at baseline, in order to evaluate the inclusion 
and exclusion criteria. 
Inclusion criteria:  
- large and/or segmental IHs  
- IHs in critical sites (e.g. ears, eyelids, nose and lips) 
- rapid growth 
- ulceration 
- possible impairment of physiological functions 
- possible evolution toward disfiguring scars 
- written informed consent 
Exclusion criteria: 
- cardiovascular diseases 
- asthma 
- hypersensivity to propranolol in first degree 
- diabetes mellitus 
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Before starting the treatment, all patients underwent both a cardiac 
evaluation including elettrocardiography, blood pressure measurement and 
baseline heart rate and pediatric evaluation with blood tests to check liver 
and renal functions and glucose levels.  
Ultrasound evaluation, especially with echo color doppler, was 
usually performed to assess the deep component, the volume and the real 
extension of the lesion. 
Patients affected by large or segmental facial IHs required head and 
neck magnetic resonance imaging (MRI), otolaryngology evaluation, 
sometimes with laryngoscopy if the segmental IHs involved the beard 
region, ophthalmological evaluation, echocardiography and thyroid 
examination to exclude PHACE syndrome. MRI was sometimes necessary 
to differentiate some IHs from vascular anomalies, to detect an internal 
involvement and to evaluate the deep extension. Moreover, MRI was 
necessary when the IHs were localized in the lumbosacral area; 
lumbosacral MRI, in children under the age of  3 months, could not have a 
good sensitivity , so the examination had to be repeated over time. 
In case of multiple IHs, cerebral and hepatic ultrasound examination 
were usually performed to exclude the presence of internal hemangiomas.  
The follow-up (consisting of dermatological evaluations with 
iconography) was performed weekly during the first month of therapy and 
then, monthly, until the treatment was concluded. All IHs were evaluated 
for color, volume and consistency and, in order to assess their evolution, a 
photographic comparison was carried out.   
Moreover, all patients were evaluated by Pediatricians for a general 
examination every week for the first month, then monthly. 
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Cardiologists conducted examinations every month and 
electrocardiographies were performed every 3 months until the end of the 
treatment. 
Usually, ultrasound examinations of the lesion were performed 
weekly at the beginning of the treatment and then monthly. 
Recommended regimen doses varied from 1 mg/kg/day to 3 
mg/kg/day divided into 3 daily doses. In our protocol, we usually started 
and continued with 2 mg/kg/day for the entire duration of the treatment; 
only in case of absence of improvement after 4 weeks, the dose could be 
increased by 0,5 mg/kg/day weekly up to 3 mg/kg/day. At the end of the 
treatment, propranolol was gradually tapered to 1 mg/kg/day per week. In 
some patients, especially in very young children, we started with 1 
mg/kg/day and we gradually increased to 2 mg/kg/day. The duration of the 
treatment could be variable, relating to the IH features and to the single 
responses to propranolol. It is generally recommended to continue the 
therapy until the proliferative phase is finished, about up to  12 months of 
life, to avoid the risk of regrowth, although some relapses could occur after 
this period. 
Results: 
Seventy-eight patients (57 females and 21 males; 2.7:1) were 
enrolled in the study. Now, in 58/78 patients (45 females and 13 males) the 
treatment has been stopped, while 19 patients (11 females and 8 males) 
have been undergoing the treatment. One girl, after the enrollment, was lost 
at follow up. 
Forty-two of the 58 patients who had completed the treatment had 
good results, without any side effects and recurrences. Six children, showed 
recurrences when the therapy was concluded despite a good response after 
the first cycle of treatment. They were re-treated with propranolol, for at 
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least 3 cycles, but 4 of these 6 patients did never show the complete 
regression of their IHs. Furthermore, they had a tendency for recurrences 
after the conclusion of every therapeutic cycle. 
In our patients, the rebound of growth occurred after an average of 3 
months (range 0-9 months) after the stop of the propranolol therapy. The 
first cycle lasted about 10 months and at the end of it the patients were aged 
on average 15 months. 
These are the features of our 6 cases of relapses which needed a 
further therapy: 
- 1) Girl, born at term, with submandibular IH: she started the 
propranolol therapy at 5 months of age, initially at dosage of 1 mg/kg/die 
for the first week, then it increased to 2 mg/kg/die and it was performed for 
9 months (until she was 14 months old), with good regression. Nine months 
after the discontinuation of the therapy, because of a relapse, she re-started 
propranolol at the same dosage for further 6 months. The IH regressed and 
the patient has been in follow up for 6 months. 
- 2) Girl, born preterm, with IH localized on her left cheek: she 
was initially treated with systemic steroid (deflazacort 2-2,5 mg/kg/die) 
with partial regression. At 9 months of age, she was treated with 
propranolol for 10 months (age of conclusion of the therapy: 20 months). 
Soon after the conclusion of the therapy a relapse occurred; the patient was 
re-treated with propranolol for a further 3 months but no improvement 
occurred, so the baby underwent a surgical treatment.  
- 3) Girl, born preterm, affected by beard hemangioma 
involving the airways: propranolol therapy was started at 2 months of age 
with a good response both of the cutaneous and the airways components. 
Therapy was stopped at the age of 16 months. The lesion relapsed after 3 
months, so that another propranolol cycle was prescribed for 3 months. 
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Eight months after the conclusion of the last cycle, regrowth occurred. The 
patient was surgically treated. 
- 4)  Boy, born at term, affected by a lip ulcerated IH: at the age 
of 2 months, he started propranolol therapy performed for 8 months (it was 
stopped at age of 10 months) with excellent results. However, after 3 
months, a regrowth was noted and the therapy was re-introduced for 9 
months (age 22 months) with only a partial regression of the lesion. After 6 
months of follow up and a consultation in the maxillo-facial surgery 
division, a third cycle of propranolol was made for 10 months with further 
improvements. The patient is currently on follow up. 
- 5) Girl, born preterm, affected by a right palpebral IH. She was 
treated with deflazacort 3 mg/kg/die for the first 3 weeks of her life. 
Propranolol was started at 1 month of age and extended up to 14 months of 
age with satisfactory results. Three weeks after the conclusion of the 
therapy, the lesion showed a regrowth, so the therapy was re-introduced for 
3 months. One month after the conclusion of that second cycle, the lesion 
still relapsed and the therapy was prescribed again for another 3 months. 
The patient is currently on follow up, a mild IH residuum is still present 
and it should be object of surgical evaluation for aesthetical improvement. 
- 6) Girl, born at term, affected by a latero-cervical IH. 
Propranolol treatment was started at 10 months of life and conducted for 5 
months then it was stopped because of the good results obtained. However, 
after only 1 month, the lesion tended to regrowth, so further propranolol 
therapy was administered until the age of 21 months. Good results were 
obtained, except for unaesthetic residual changes which could be surgically 
treated after a surgeon consultation. 
6/58 patients did not respond to the beta blockers: 4 patients 
underwent surgery treatment, 1 patient was treated with systemic 
 29 
corticosteroid with poor response and 1 patient was treated with topical 
propranolol. 
Features of the 6 patients:  
-  1) Girl, born preterm, affected by a voluminous and ulcerated IH 
localized in the left parietal region. She had been treated with propranolol 
since the age of 5 months until 11 months. The superficial component of 
the IH regressed, the deep component did not respond to the therapy and a 
surgical treatment was suggested. 
- 2) Girl, born preterm, affected by an ulcerated IH sited on her right 
arm: propranolol had been  administered since the age of 7 months until the 
age of 14 months, initially at the dosage of 2 mg/kg/die and gradually 
increased up to 5 mg/kg/die without any response. An early (when she was 
15 months) surgical treatment was suggested. 
- 3) Girl, born at term, affected by a fast growing, ulcerated lip IH: at 
the beginning she was treated with corticosteroid (deflazacort 3 mg/kg/die) 
when she was 3 months old with partial response. At the age of 21 months 
she started propranolol, continued for 7 months. The lesion improved but it 
did not totally regress, so she was surgically treated. 
- 4) Boy, born at term, affected by a deep periorbital IH. We 
performed a late intervention: the patient was 4 years old when a 
propranolol therapy was attempted for 2 months without any response. 
Then, the patient had a surgical treatment. 
- 5) Boy, born preterm, affected by a facial segmental right IH 
involving palpebral area: propranolol therapy was started at 4 months of 
age at the dosage of 2 mg/kg/die for 1 month, then it was increased up to 3 
mg/kg/die because of the absence of response. This dosage was extended 
until the first year of life without regression. The patient has currently been 
treated with systemic corticosteroid (deflazacort 5 mg/kg/die). 
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- 6) Boy, born preterm, affected by   a   “Cyrano  hemangioma”   :   this  
patient was firstly treated with systemic corticosteroid (deflazacort 3 
mg/kg/die) for 40 days; propranolol was started at the age of 9 months until 
11 months, with improvement of the deep component but with an 
unaesthetic telangiectasic residuum. “Cyrano   hemangioma”   identified   an 
IH localized at the tip of the nose which could lead to unaesthetic 
deformities. In agreement with the literature, it usually shows poor 
response to propranolol therapy. In our patient, a flat unaesthetic lesion 
persisted after systemic propranolol administration, so he was treated with 
topical propranolol (galenic formulation propranolol 1% cream) for 3 
months looking forward to a potential future laser treatment. 
Propranolol treatment was early stopped in 4 of 58 patients because 
of the onset of the following side effects: 
1) Behaviour modification with irritability, sleep disturbances 
and neurological tics appeared in a 9-month-old girl, born at term, affected 
by 2 IHs, localized in the nose and in the thorax. Neurological evaluation 
excluded the propranolol involvement in the tics, however propranolol was 
stopped and the neurological tics spontaneously disappeared. 
2) Hypoglycemia appeared in a girl, born at term, affected by a 
submandibular IH. The treatment was stopped after 2 months of therapy 
because of a hypoglycemic episode. Nevertheless, IH continued to 
spontaneously regress. Beta blockers may reduce gluconeogenesis, 
glycogenolysis and lipolysis increasing the risks of hypoglycemic episodes. 
Moreover, they may hide the signs of hypoglycemia. Hypoglycemia is 
more frequent when propranolol is administered in premature children at 
high dosage: our girl was 24 months old when propranolol was started as a 
delayed treatment of a submandibular hemangioma at the standard dosage 
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of 2 mg/kg/die. She had an episode of high temperature and convulsion 
with hypoglycemia. 
3) Asmatiform bronchitic episodes appeared in a girl, born at 
term, affected by an ulcerated lip IH, during the propranolol treatment. The 
first episode needed the temporary stop of the therapy, then propranolol 
was reintroduced, but only after 1 month a similar second episode occurred. 
This episode required systemic steroids and antibiotics therapy so 
propranolol treatment was definitely stopped. The patient started 
application of topical beta blocker with good results. 
4) Unspecified side effects referred by parents after only 2 days 
of therapy: parents decided to immediately stop the therapy. This patient 
was a preterm girl, affected by an abdominal IH, who started propranolol at 
5 months of age. 
Nineteen patients are currently under treatment: all of them show a 
good response to the therapy; in this group no side effects have been 
observed until now. Two of these patients have been treated for the second 
time with propranolol because of the recurrences occurred after stopping 
the first cycle. These 2 patients showed recurrences 5 and 12 months after 
therapy cessation.  
Despite the good results, a large part of patients showed residual 
changes after the discontinuation of the propranolol therapy. However 
these changes were mild and no further systemic therapy was required. 
Although topical beta blockers application is an off-label therapy, 
considering the encouraging literature data, we decided to prescribe this 
treatment to some patients.   In   our   outpatients’   clinic, some telangiectasic 
residuum of mixed hemangiomas previously treated with systemic 
propranolol, have been successfully treated with topical propranolol.  Some 
patients were treated after the systemic propranolol therapy to reduce the 
 32 
residual teleangiectasic vessels, others were treated before the systemic 
therapy in order to avoid or to procrastinate the last one.  
Of the 78 patients treated with systemic propranolol, 9 patients 
received an additional topical beta blockers therapy. Eight patients applied 
topical beta blockers after systemic propranolol therapy in order to improve 
the aesthetic outcome and to reduce the risks of rebound of growth, 
whereas 1 patient applied timolol maleate solution before the start of the 
systemic therapy. Despite the application of topical timolol solution after 
the systemic therapy, one patient showed recurrence of the lesion and 
needed a second systemic propranolol administration. The duration of 
topical treatment depended on the response and varied from patient to 
patient.  
Further 46 children (35 females, 11 males), affected by superficial 
IHs who did not require any other systemic therapies, were treated using 
topical beta blockers in order to improve the aesthetic outcome. All of them 
showed a good response without any side effects.  
In summary, considering the whole group of our patients, (78 
patients, 57 females and 21 males), we can establish that at the beginning 
of the therapy the mean age was 6 months; the mean period of propranolol 
treatment was 7,6 months. 
58/78 patients completed the therapy: 47 with a good response (81%) 
(but 2 relapses and 3 early suspension for side effects)  
6/58 (10,3%) patients showed recurrences which needed further 
systemic therapy  
6/58 (10,3%) patients did not respond to the therapy  
4/58 (6,9%) patients showed side effects and early stopped the 
therapy  
9/78 (11,5%) patients received further topical beta blocker therapy  
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19/78 (100%) patients are still undergoing the therapy with a good 
response  
1/78 (1,3%) patient was lost at follow up  
Data of patients: 
30/78 (38,5%) patients are preterm babies  
6/78 (7,7%) patients are twins  
20/78 (25,6%) patients whose mothers underwent instrumental 
diagnostic examinations during gestations (amniocentesis and chorionic 
villous sampling)  
IHs Localization: (total number of IHs, considering that 11 patients 
showed more than one hemangioma) 
- 53 IHs localized in  the head and neck region: 10 periocular 
region, 3 beard hemangiomas with airways involvement 
- 18 in the extremities 
- 14 in the trunk 
- 3 in the ano-genital region 
- 4 patients had multiple hemangiomas: 2 with internal 
involvement, 1 of these is affected by hemangiomatosis  
- 11 patients showed more than one IHs 
- 9 patients showed segmental hemangiomas: 6 head and neck, 2  
limbs, 1 lumbo-sacral (without internal involvement)  
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7.   CONCLUSIONS 
 
In our experience, systemic propranolol at dosage of 2 mg/kg/day is 
an effective and safe treatment for IHs. Even if it is an off-label therapy, 
because it is still not approved for the IHs treatment, we consider it as the 
first choice for this kind of pathology. In fact, all the traditional therapies 
show less efficacy and more risks and side effects.  
We would like to underline the necessity of a multidisciplinary 
approach when rare and complex IHs need to be treated. A team of 
physicians is necessary to adequately treat these patients and to follow 
them up, especially because of their very young age.  
We tried to give some guidelines for the treatment of IHs: in fact, we 
provided a treatment protocol for complex IHs with a multidisciplinary 
approach to the patient recruitment and follow-up. It indicates dosage, 
monitoring and management of side effects, minimum duration of the 
treatment (at least until the end of the era of proliferation around the first 
year of life of the patient), treatment of relapses, management of non-
responder patients and any aesthetic results once the therapy was 
completed. 
In agreement with the literature, we observed greater risks of IHs in 
females than in males, in preterm babies and when amniocentesis or 
chorionic villous sampling were performed during gestation. Main 
localization is the head and neck region, followed by the extremities and 
the trunk.  
Younger patients showed more benefits from propranolol therapy 
than older ones after the post-proliferative phase. However, some older 
patients received the treatment as first line-therapy with good clinical 
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improvement. So we confirm the opportunity of propranolol administration 
even if the proliferative phase is completed. 
The mechanisms of propranolol-induced regression of IHs are not 
fully understood yet, but progresses have been made and in the future they 
will be better explained.  However, we noticed the early effect that 
propranolol has on IHs due to vasoconstriction which is already evident in 
the first 48 hours; then we observed the intermediate and late effects which 
allow to induce and stabilize the regression of the IHs. We remarked an 
important difference in the various IHs we treated, both in the speed of 
response to propranolol and in the extent of the regression obtained, 
besides in the maintenance of the results at the end of therapy. According 
to the literature, we believe that there is a marked variability not only 
clinical but also in the behavior of IHs; this factor may explain why not all 
IHs, regardless of the type and location, respond in the same way, at the 
same rate, with the same risk of recurrences and long-term results. 
Some IHs show a certain resistance to the therapy, regardless of the 
period of life when the administration starts and the therapy is completed. 
This hypothetical resistance may be the cause of the non-responder 
patients and of the relapses which occur even when the treatment is 
completed in its post-proliferative phase and do not fully respond to the 
readministration of the drug. 
In our cases relapses are not attributable to an early treatment 
withdrawal, except in one patient. They are likely to be due to the intrinsic 
characteristics of these IHs, that act as "exceptions". 
In some cases recurrences may indicate that the proliferative phase of 
the IHs is probably still ongoing and that some IHs have a late proliferative 
phase. However, it is very difficult to predict which IHs will show this 
behavior. The exact mechanism underlying the late proliferative phase is 
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unknown: apoptosis of the endothelial cells is the best mechanism involved 
in the natural involution of IHs and propranolol is known to induce 
apoptosis. However, in some cases apoptosis could be not completed after 
propranolol withdrawal. The VEGF expression is involved in the 
proliferative phase of IHs and propranolol inhibits endothelial proliferation, 
antagonizing the VEGF receptors at the same time: probably these 
receptors are also involved in the recurrences after propranolol stop.  
With regard to the side effects we observed, they were mild, in line 
with the data provided by the literature and they disappeared when the drug 
was stopped. 
Even in patients in follow-up for more than one year after the end of 
the therapy (19/58 patients, 32.8%) we found no side effects related to the 
previous therapy with propranolol. Our experience allows us to confirm 
that the treatment with propranolol is well tolerated and with a good safety 
profile.  
Further comparative studies are needed to determine the most 
effective dosage and the optimum duration of the treatment as well as large 
long-term studies in order to understand the risk of late adverse events.  
Some patients received topical beta blockers to improve the aesthetic 
outcome: in our experience topical beta blockers therapy is effective and 
safe; no systemic and localized side effects have been recorded until now. 
Obviously a longer follow up period and a larger number of treated patients 
are necessary to draw interesting conclusions about the efficacy, the 
tolerability and the duration of the topical therapy. 
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m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
Pr
ev
io
us
 th
er
ap
ie
s 
—
 
—
 
—
 
—
 
Pe
rio
d 
of
 th
e 
th
er
ap
y 
w
ith
 p
ro
pr
an
ol
ol
 
7 
m
on
th
s 
4 
m
on
th
s 
4 
m
on
th
s 
4 
m
on
th
s 
IH
 R
es
po
ns
e 
G
oo
d 
G
oo
d 
G
oo
d 
G
oo
d 
R
ec
ur
re
nc
es
 
—
 
—
 
R
eg
ro
w
th
 w
ith
ou
t 
th
er
ap
y 
af
te
r 1
 y
ea
r 
—
 
Fu
rth
er
 c
yc
le
 w
ith
 
Pr
op
ra
no
lo
l 
—
 
—
 
3 
m
on
th
s, 
st
ill
 in
 th
er
ap
y 
—
 
A
no
th
er
 th
er
ap
y 
—
 
—
 
—
 
—
 
Ev
en
ts
 d
ur
in
g 
th
e 
th
er
ap
y 
—
 
—
 
—
 
—
 
Si
de
 e
ff
ec
ts
 
—
 
—
 
—
 
—
 
Ea
rly
 c
on
cl
us
io
n 
of
 th
e 
th
er
ap
y 
—
 
—
 
—
 
—
 
In
st
ru
m
en
ta
l t
ex
ts
 in
 th
e 
pr
eg
na
nt
 m
ot
he
r 
—
 
—
 
—
 
—
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PA
TI
EN
TS
 W
HO
 C
OM
PL
ET
ED
 T
HE
 T
HE
RA
PY
 
Pa
tie
nt 
20
 
21
 
22
 
23
 
24
 
Se
x 
M
al
e 
M
al
e 
M
al
e 
M
al
e 
M
al
e 
B
irt
h 
Pr
et
er
m
 
A
t t
er
m
 
A
t t
er
m
 
Pr
et
er
m
 
A
t t
er
m
 
IH
 L
oc
al
iz
at
io
n 
C
on
ju
nc
tiv
a,
 S
id
e 
an
d 
Fo
ot
 
Te
m
po
ro
-p
ar
ie
ta
l a
re
a 
an
d 
Sh
ou
ld
er
 
M
ul
tip
le
 
Fa
ci
al
 se
gm
en
ta
l w
ith
 
pa
lp
eb
ra
l i
nv
ol
ve
m
en
t 
Pa
lp
eb
ra
 
In
te
rn
al
 IH
 
—
 
—
 
Li
ve
r 
—
 
—
 
A
ge
 a
t o
ns
et
 
—
 
—
 
—
 
—
 
—
 
A
ge
 a
t o
ns
et
 o
f t
he
 
th
er
ap
y 
w
ith
 P
ro
pr
an
ol
ol
 
4-
m
on
th
s-
ol
d 
4-
m
on
th
s-
ol
d 
2-
m
on
th
s-
ol
d 
4-
m
on
th
s-
ol
d 
4-
m
on
th
s-
ol
d 
D
os
ag
e 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 th
en
 
3 
m
g/
kg
/d
ay
 d
ue
 to
 p
oo
r 
re
sp
on
se
 
1,
3 
m
g/
kg
/d
ay
 fo
r 1
 
m
on
th
, t
he
n 
2 
m
g/
kg
/d
ay
 
Pr
ev
io
us
 th
er
ap
ie
s 
—
 
—
 
—
 
—
 
—
 
Pe
rio
d 
of
 th
e 
th
er
ap
y 
w
ith
 p
ro
pr
an
ol
ol
 
11
 m
on
th
s 
4 
m
on
th
s 
9 
m
on
th
s 
8 
m
on
th
s 
7 
m
on
th
s 
A
ge
 a
t t
he
 e
nd
 o
f t
he
  
th
er
ap
y 
w
ith
 P
ro
pr
an
ol
ol
 
15
-m
on
th
s-
ol
d 
8-
m
on
th
s-
ol
d 
11
-m
on
th
s-
ol
d 
12
-m
on
th
s-
ol
d 
11
-m
on
th
s-
ol
d 
IH
 R
es
po
ns
e 
G
oo
d 
G
oo
d 
G
oo
d:
 sl
ig
ht
 in
cr
ea
se
 o
f 
su
pe
rf
ic
ia
l 
te
la
ng
ie
ct
as
ia
s 
Po
or
 
G
oo
d 
R
ec
ur
re
nc
es
 
—
 
—
 
—
 
—
 
—
 
Fu
rth
er
 c
yc
le
 w
ith
 
Pr
op
ra
no
lo
l 
—
 
—
 
—
 
—
 
—
 
A
no
th
er
 th
er
ap
y 
—
 
—
 
To
pi
ca
l B
et
a 
Bl
oc
ke
r 
Sy
st
em
ic
 C
or
tic
os
te
ro
id
 
—
 
Ti
m
e 
of
 th
e 
fo
llo
w
 u
p 
af
te
r t
he
ra
py
 su
sp
en
si
on
 
6 
m
on
th
s 
1 
ye
ar
 
3 
m
on
th
s 
1 
m
on
th
 
14
 m
on
th
s 
Ill
ne
ss
 d
ur
in
g 
th
e 
th
er
ap
y 
—
 
—
 
V
ira
l e
xa
nt
he
m
a:
 d
ur
in
g 
th
is
 p
er
io
d 
(2
 w
ee
ks
) 
pr
op
ra
no
lo
l w
as
 st
op
pe
d 
th
en
 re
in
tro
du
ce
d 
—
 
—
 
Si
de
 e
ff
ec
ts
 
—
 
—
 
—
 
—
 
—
 
Ea
rly
 c
on
cl
us
io
n 
of
 th
e 
th
er
ap
y 
—
 
—
 
—
 
—
 
—
 
In
st
ru
m
en
ta
l t
ex
ts
 in
 th
e 
pr
eg
na
nt
 m
ot
he
r 
—
 
C
ho
rio
ni
c 
V
ill
ou
s 
Sa
m
pl
in
g 
C
ho
rio
ni
c 
V
ill
ou
s 
Sa
m
pl
in
g 
—
 
C
ho
rio
ni
c 
V
ill
ou
s 
Sa
m
pl
in
g 
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 Pa
tie
nt 
 
25
 
26
 
27
 
28
 
29
 
Se
x 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
B
irt
h 
Pr
et
er
m
, T
w
in
 
Pr
et
er
m
 
Pr
et
er
m
, C
on
ge
ni
ta
l 
C
M
V
 a
t 2
4 
w
ee
ks
 o
f 
pr
eg
na
nc
y 
A
t t
er
m
 
A
t t
er
m
 
IH
 L
oc
al
iz
at
io
n 
Sh
ou
ld
er
 
M
ul
tip
le
 
A
rm
 w
ith
 u
lc
er
at
io
n 
C
he
st
 a
nd
 N
os
e 
B
ac
k 
In
te
rn
al
 IH
 
—
 
—
 
—
 
—
 
—
 
A
ge
 a
t o
ns
et
 
—
 
A
t b
irt
h 
3-
da
ys
-o
ld
 
—
 
—
 
A
ge
 a
t o
ns
et
 o
f t
he
 
th
er
ap
y 
w
ith
 P
ro
pr
an
ol
ol
 
10
-m
on
th
s-
ol
d 
3-
m
on
th
s-
ol
d 
7-
m
on
th
s-
ol
d 
5-
m
on
th
s-
ol
d 
7-
m
on
th
s-
ol
d 
D
os
ag
e 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 th
en
 
5 
m
g/
kg
/d
ay
 d
ue
 to
 p
oo
r 
re
sp
on
se
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
 
Pr
ev
io
us
 th
er
ap
ie
s 
—
 
—
 
—
 
—
 
—
 
Pe
rio
d 
of
 th
e 
th
er
ap
y 
w
ith
 p
ro
pr
an
ol
ol
 
7 
m
on
th
s 
11
 m
on
th
s 
6 
m
on
th
s 
4 
m
on
th
s 
7 
m
on
th
s 
A
ge
 a
t t
he
 e
nd
 o
f t
he
 
th
er
ap
y 
w
ith
 P
ro
pr
an
ol
ol
 
17
-m
on
th
s-
ol
d 
14
-m
on
th
s-
ol
d 
14
-m
on
th
s-
ol
d 
9-
m
on
th
s-
ol
d 
14
-m
on
th
s-
ol
d 
IH
 R
es
po
ns
e 
G
oo
d 
G
oo
d 
A
bs
en
t 
G
oo
d 
G
oo
d 
R
ec
ur
re
nc
es
 
—
 
—
 
—
 
—
 
Sl
ig
ht
 re
gr
ow
th
 
Fu
rth
er
 c
yc
le
 w
ith
 
Pr
op
ra
no
lo
l 
—
 
—
 
—
 
—
 
—
 
A
no
th
er
 th
er
ap
y 
—
 
—
 
Su
rg
er
y 
—
 
—
 
Ti
m
e 
of
 th
e 
fo
llo
w
 u
p 
af
te
r t
he
ra
py
 su
sp
en
si
on
 
—
 
1 
m
on
th
 
1 
m
on
th
 
2 
m
on
th
s 
1 
ye
ar
 
Ill
ne
ss
 d
ur
in
g 
th
e 
th
er
ap
y 
—
 
—
 
—
 
—
 
—
 
Si
de
 e
ff
ec
ts
 
—
 
—
 
—
 
Sl
ee
p-
w
ak
e 
irr
ita
bi
lit
y 
an
d 
ph
ys
ic
al
 T
IC
S 
(a
ny
w
ay
 a
ttr
ib
ut
ab
le
 to
 
st
re
ss
) 
—
 
Ea
rly
 c
on
cl
us
io
n 
of
 th
e 
th
er
ap
y 
—
 
—
 
—
 
B
ec
au
se
 o
f t
he
 si
de
 
ef
fe
ct
s 
—
 
In
st
ru
m
en
ta
l t
ex
ts
 in
 th
e 
pr
eg
na
nt
 m
ot
he
r 
C
ho
rio
ni
c 
V
ill
ou
s 
Sa
m
pl
in
g 
—
 
A
m
ni
oc
en
te
si
s 
—
 
—
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Pa
tie
nt 
30
 
31
 
32
 
33
 
34
 
Se
x 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
B
irt
h 
A
t t
er
m
 
Pr
et
er
m
 
Pr
et
er
m
 
A
t t
er
m
 
Pr
et
er
m
 
IH
 L
oc
al
iz
at
io
n 
N
os
e 
N
os
e 
(C
yr
an
o)
 
Fr
on
t 
V
ul
va
 
A
bd
om
en
 
In
te
rn
al
 IH
 
—
 
—
 
—
 
—
 
—
 
A
ge
 a
t o
ns
et
 
1/
2-
m
on
th
s-
ol
d 
—
 
—
 
—
 
—
 
A
ge
 a
t o
ns
et
 o
f t
he
 
th
er
ap
y 
w
ith
 P
ro
pr
an
ol
ol
 
4-
m
on
th
s-
ol
d 
5-
m
on
th
s-
ol
d 
3-
m
on
th
s-
ol
d 
4-
m
on
th
s-
ol
d 
5-
m
on
th
s-
ol
d 
D
os
ag
e 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
Pr
ev
io
us
 th
er
ap
ie
s 
—
 
—
 
—
 
—
 
—
 
Pe
rio
d 
of
 th
e 
th
er
ap
y 
w
ith
 p
ro
pr
an
ol
ol
 
4 
m
on
th
s 
7 
m
on
th
s 
9 
m
on
th
s 
9 
m
on
th
s 
2 
da
ys
 
A
ge
 a
t t
he
 e
nd
 o
f t
he
 
th
er
ap
y 
w
ith
 P
ro
pr
an
ol
ol
 
8-
m
on
th
s-
ol
d 
12
-m
on
th
s-
ol
d 
12
-m
on
th
s-
ol
d 
13
-m
on
th
s-
ol
d 
—
 
IH
 R
es
po
ns
e 
Ex
ce
lle
nt
 
G
oo
d 
G
oo
d 
G
oo
d 
Sp
on
ta
ne
ou
s r
eg
re
ss
io
n 
w
he
n 
sh
e 
w
as
 1
 y
ea
r o
ld
 
R
ec
ur
re
nc
es
 
—
 
Sl
ig
ht
 re
gr
ow
th
 w
ith
ou
t 
th
er
ap
y 
af
te
r 3
 m
on
th
s 
—
 
—
 
—
 
Fu
rth
er
 c
yc
le
 w
ith
 
Pr
op
ra
no
lo
l 
—
 
—
 
—
 
—
 
—
 
A
no
th
er
 th
er
ap
y 
—
 
To
pi
ca
l B
et
a 
Bl
oc
ke
r 
(g
oo
d 
re
sp
on
se
 a
fte
r 2
 
m
on
th
s)
 
To
pi
ca
l B
et
a 
Bl
oc
ke
r 
—
 
—
 
Ti
m
e 
of
 th
e 
fo
llo
w
 u
p 
af
te
r t
he
ra
py
 su
sp
en
si
on
 
3 
m
on
th
s 
6 
m
on
th
s 
7 
m
on
th
s 
9 
m
on
th
s 
6 
m
on
th
s 
Ill
ne
ss
 d
ur
in
g 
th
e 
th
er
ap
y 
—
 
—
 
—
 
—
 
—
 
Si
de
 e
ff
ec
ts
 
—
 
—
 
—
 
—
 
Po
or
ly
 to
le
ra
te
d 
Ea
rly
 c
on
cl
us
io
n 
of
 th
e 
th
er
ap
y 
—
 
—
 
—
 
—
 
U
ns
pe
ci
fic
 si
de
 e
ff
ec
ts
 
In
st
ru
m
en
ta
l t
ex
ts
 in
 th
e 
pr
eg
na
nt
 m
ot
he
r 
—
 
C
ho
rio
ni
c 
V
ill
ou
s 
Sa
m
pl
in
g 
A
m
ni
oc
en
te
si
s 
—
 
—
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Pa
tie
nt 
 
35
 
36
 
37
 
38
 
39
 
Se
x 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
B
irt
h 
A
t t
er
m
 
A
t t
er
m
 
Pr
et
er
m
 
Pr
et
er
m
 
Pr
et
er
m
 
IH
 L
oc
al
iz
at
io
n 
Li
p 
A
bd
om
en
 
O
cc
ip
ite
 
R
et
ro
au
ric
ul
ar
 
Th
ig
h 
In
te
rn
al
 IH
 
—
 
—
 
—
 
—
 
—
 
A
ge
 a
t o
ns
et
 
A
t B
irt
h 
—
 
—
 
4/
5-
da
ys
-o
ld
 
—
 
A
ge
 a
t o
ns
et
 o
f t
he
 
th
er
ap
y 
w
ith
 P
ro
pr
an
ol
ol
 
2-
m
on
th
s-
ol
d 
4-
m
on
th
s-
ol
d 
12
-m
on
th
s-
ol
d 
3-
m
on
th
s-
ol
d 
4-
m
on
th
s-
ol
d 
D
os
ag
e 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
Pr
ev
io
us
 th
er
ap
ie
s 
—
 
—
 
—
 
—
 
—
 
Pe
rio
d 
of
 th
e 
th
er
ap
y 
w
ith
 p
ro
pr
an
ol
ol
 
7 
m
on
th
s 
10
 m
on
th
s 
7 
m
on
th
s 
9 
m
on
th
s 
6 
m
on
th
s 
A
ge
 a
t t
he
  e
nd
 o
f t
he
 
th
er
ap
y 
w
ith
 P
ro
pr
an
ol
ol
 
9-
m
on
th
s-
ol
d 
14
-m
on
th
s-
ol
d 
19
-m
on
th
s-
ol
d 
12
-m
on
th
s-
ol
d 
10
-m
on
th
s-
ol
d 
IH
 R
es
po
ns
e 
G
oo
d 
G
oo
d 
G
oo
d 
Ex
ce
lle
nt
 
Ex
ce
lle
nt
 
R
ec
ur
re
nc
es
 
—
 
—
 
—
 
—
 
—
 
Fu
rth
er
 c
yc
le
 w
ith
 
Pr
op
ra
no
lo
l 
—
 
—
 
—
 
—
 
—
 
A
no
th
er
 th
er
ap
y 
To
pi
ca
l B
et
a 
Bl
oc
ke
r d
ue
 
to
 th
in
 v
es
se
ls
 
To
pi
ca
l B
et
a 
Bl
oc
ke
r 
—
 
—
 
—
 
Ti
m
e 
of
 th
e 
fo
llo
w
 u
p 
af
te
r t
he
ra
py
 su
sp
en
si
on
 
9 
m
on
th
s 
5 
m
on
th
s 
1 
m
on
th
 
4 
m
on
th
s 
10
 m
on
th
s 
Ill
ne
ss
 d
ur
in
g 
th
e 
th
er
ap
y 
2 
ep
is
od
es
 o
f a
sm
at
ifo
rm
 
br
on
ch
iti
s d
ur
in
g 
th
e 
la
st
 
m
on
th
 o
f t
he
ra
py
. 
In
iti
al
ly
 p
ro
pr
an
ol
ol
 w
as
 
te
m
po
ra
ril
y 
in
te
rr
up
te
d,
 
th
en
 d
ef
in
iti
ve
ly
 st
op
pe
d 
—
 
—
 
—
 
—
 
Si
de
 e
ff
ec
ts
 
A
sm
at
ifo
rm
 b
ro
nc
hi
tis
 
—
 
—
 
—
 
—
 
Ea
rly
 c
on
cl
us
io
n 
of
 th
e 
th
er
ap
y 
Y
es
, w
he
n 
sh
e 
w
as
 9
 
m
on
th
s o
ld
. T
he
n 
to
pi
ca
l 
be
ta
 b
lo
ck
er
 w
as
 a
pp
lie
d 
 
—
 
—
 
—
 
—
 
In
st
ru
m
en
ta
l t
ex
ts
 in
 th
e 
pr
eg
na
nt
 m
ot
he
r 
—
 
—
 
—
 
A
m
ni
oc
en
te
si
s 
—
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Pa
tie
nt 
 
40
 
41
 
42
 
43
 
44
 
Se
x 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
B
irt
h 
Pr
et
er
m
 
A
t t
er
m
 
A
t t
er
m
 
A
t t
er
m
 
A
t t
er
m
 
IH
 L
oc
al
iz
at
io
n 
Li
p 
A
rm
 
Sh
ou
ld
er
 
Su
bm
an
di
bu
la
r 
Pa
ro
tid
 
In
te
rn
al
 IH
 
—
 
—
 
—
 
—
 
—
 
A
ge
 a
t o
ns
et
 
—
 
—
 
—
 
—
 
—
 
A
ge
 a
t o
ns
et
 o
f t
he
 
th
er
ap
y 
w
ith
 P
ro
pr
an
ol
ol
 
4-
m
on
th
s-
ol
d 
11
-m
on
th
s-
ol
d 
9-
m
on
th
s-
ol
d 
24
-m
on
th
s-
ol
d 
(la
te
 st
ar
t) 
10
-m
on
th
s-
ol
d 
D
os
ag
e 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
2 
m
g/
kg
/d
ay
 
Pr
ev
io
us
 th
er
ap
ie
s 
—
 
—
 
—
 
—
 
—
 
Pe
rio
d 
of
 th
e 
th
er
ap
y 
w
ith
 p
ro
pr
an
ol
ol
 
5 
m
on
th
s 
4 
m
on
th
s 
6 
m
on
th
s 
2 
m
on
th
s 
—
 
A
ge
 a
t t
he
 e
nd
 o
f t
he
  
th
er
ap
y 
w
ith
 P
ro
pr
an
ol
ol
 
9-
m
on
th
s-
ol
d 
15
-m
on
th
s-
ol
d 
15
-m
on
th
s-
ol
d 
26
-m
on
th
s-
ol
d 
—
 
IH
 R
es
po
ns
e 
G
oo
d 
G
oo
d 
G
oo
d 
St
ab
le
 re
gr
es
si
on
 a
fte
r 6
 
m
on
th
s 
—
 
R
ec
ur
re
nc
es
 
—
 
Sl
ig
ht
 re
cu
rr
en
ce
 a
fte
r 3
 
m
on
th
s 
—
 
—
 
—
 
Fu
rth
er
 c
yc
le
 w
ith
 
Pr
op
ra
no
lo
l 
—
 
—
 
—
 
—
 
—
 
A
no
th
er
 th
er
ap
y 
—
 
—
 
—
 
—
 
—
 
Ti
m
e 
of
 th
e 
fo
llo
w
 u
p 
af
te
r t
he
ra
py
 su
sp
en
si
on
 
4 
m
on
th
s 
3 
m
on
th
s 
2 
m
on
th
s 
6 
m
on
th
s 
Lo
st
 a
t f
ol
lo
w
 u
p 
Ill
ne
ss
 d
ur
in
g 
th
e 
th
er
ap
y 
—
 
—
 
—
 
—
 
—
 
Si
de
 e
ff
ec
ts
 
—
 
—
 
—
 
H
yp
og
ly
ca
em
ic
 e
pi
so
de
 
—
 
Ea
rly
 c
on
cl
us
io
n 
of
 th
e 
th
er
ap
y 
—
 
—
 
—
 
A
fte
r h
yp
og
ly
ca
em
ic
 
ep
is
od
e 
—
 
In
st
ru
m
en
ta
l t
ex
ts
 in
 th
e 
pr
eg
na
nt
 m
ot
he
r 
—
 
—
 
—
 
—
 
—
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Pa
tie
nt 
 
45
 
46
 
47
 
48
 
49
 
Se
x 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
Fe
m
al
e 
B
irt
h 
A
t t
er
m
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10.   PICTURES 
 
 
 
 
 
1) Girl at 2 months of age, affected by an ulcerated lip and nasal IH. 
 
 
 
 
2) The same patient at 7 months of age, after 5 months of propranolol 2 mg/kg/day 
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3) 4-months-old girl, affected by a voluminous abdominal IH. 
 
 
 
1) The same girl al 19 months of age, after 10 months of systemic propranolol 2 
mg/kg/day and 4 months of topical beta blocker. 
